Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, Via Camillo Rosalba 35/37, 70124, Bari, Italy.
Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.
J Cardiothorac Surg. 2023 Mar 30;18(1):95. doi: 10.1186/s13019-023-02190-9.
The management of the oxygenator can be prolonged in the long-term procedures especially during extracorporeal membrane oxygenation (ECMO) for bridge to transplant or bridge to recovery. Long-term use often involves an overrun of the time of use with respect to certification of the oxygenating module of 14 days, for the maintenance of performance and efficiency of the oxygenator. The evaluation of the long-term oxygenator efficiency is complex and depends on the: patient pathology, ECMO configuration, the management of coagulation and anticoagulation, materials selection and circuit components, the structure, design and performance of the oxygenator. In this context we investgated the long-term performance of the A.L.ONE Eurosets ECMO oxygenator in relation to the parameters prodromal to replacement.
We retrospectively collected eight years data from Anthea Hospital GVM Care & Research, Bari, Italy on the long-term use exceeding 14 days of Eurosets A.L.ONE ECMO Adult oxygenator in Polymetylpentene fiber, for ECMO procedures, including the procedures: Veno Arterial (VA) ECMO post-cardiotomy or not, veno-venous (VV) ECMO. The primary end points were the evaluation of Gas Transfer: oxygen partial pressure (PO) post oxygenator, Carbon dioxide partial pressure (PCO) post oxygenator, the oxygen transfer across the oxygenator membrane V'O, differential CO content across oxygenator; Pressure monitoring: oxygenator pressure Drop in relation to Blood flow rate (BFR) (ΔP); Hematologic values: Hemoglobin, Fibrinogen, Platelets, aPTT, D-Dimer, LDH.
Nine VA ECMO patients who used the oxygenator for 18.5 days and two VV ECMO patients who used the oxygenators for 17.2 days on the seventeenth days reported average values PaO (267 ± 29 mmHg); PaCO (34 ± 4 mmHg) with gas blender values set to 3.8 ± 0.6 L/min of air and a FiO of 78 ± 5%; the transfer across the oxygenator membrane V'O was 189 ± 43 (ml/min/m). The mean peak of partial pressure of carbon dioxide from the gas exhaust of oxygenator (PCO) was 38 ± 4 mmHg; differential CO across the oxygenator "pre-oxygenator PCO-post-oxygenator PCO" (18 ± 6 mmHg); the mean blood flow rate (BFR) 4.5 ± 0.6 (L/minute); the pump revolution per minutes mean maximum rate was 4254 ± 345 (RPM); the mean pressure drop (ΔP) was 76 ± 12 mmHg; the mean peak of d-dimers (DDs) was 23.6 ± 0.8 mg / dL; the mean peak of LDH was 230 ± 55 (mg/dl); fibrinogen mean peak 223 ± 40 (mg/dl).
The performance of the Eurosets A.L.ONE ECMO Adult polymethylpentene fiber oxygenator in our experience has proven efficiency in terms of O uptake and CO removal, blood fluid dynamics, metabolic compensation and heat exchange in the long-term treatment. The device was safe without iatrogenic problems over a period of 14 days in the patients undergoing ECMO VA and in all patients undergoing VV ECMO with continuous administration of anticoagulation therapy.
在长期程序中,特别是在体外膜肺氧合 (ECMO) 桥接移植或桥接恢复期间,可以延长氧合器的管理。长期使用通常涉及超过 14 天的氧合模块认证时间的使用时间延长,以维持氧合器的性能和效率。长期氧合器效率的评估很复杂,取决于:患者病理、ECMO 配置、凝血和抗凝管理、材料选择和回路组件、氧合器的结构、设计和性能。在这种情况下,我们调查了 A.L.ONE Eurosets ECMO 氧合器的长期性能与替代前参数之间的关系。
我们回顾性地收集了意大利巴里 Anthea 医院 GVM Care & Research 长达八年的数据,这些数据涉及使用聚甲基戊烯纤维的 A.L.ONE ECMO 成人氧合器进行超过 14 天的 ECMO 程序,包括以下程序:心手术后的静脉动脉 (VA) ECMO 或非心手术后的静脉-静脉 (VV) ECMO。主要终点是评估气体转移:氧合器后氧分压 (PO)、氧合器后二氧化碳分压 (PCO)、氧合器膜透过的氧转移量 (V'O)、氧合器内 CO 差分布;压力监测:与血流量 (BFR) 相关的氧合器压降 (ΔP);血液学值:血红蛋白、纤维蛋白原、血小板、aPTT、D-二聚体、LDH。
9 名接受 VA ECMO 的患者使用氧合器 18.5 天,2 名接受 VV ECMO 的患者使用氧合器 17.2 天,在第 17 天报告了平均 PaO(267 ± 29 mmHg)值;PaCO(34 ± 4 mmHg),空气混合器值设置为 3.8 ± 0.6 L/min,FiO 为 78 ± 5%;氧合器膜透过的氧转移量为 189 ± 43(ml/min/m)。从氧合器气体排气中测量的二氧化碳分压峰值 (PCO) 平均为 38 ± 4 mmHg;氧合器内 CO 差分布“预氧合器 PCO-后氧合器 PCO”(18 ± 6 mmHg);平均血流速度 (BFR) 4.5 ± 0.6(L/min);泵每分钟最高转速平均为 4254 ± 345(RPM);平均压降 (ΔP) 为 76 ± 12 mmHg;平均 d-二聚体峰值 (DDs) 为 23.6 ± 0.8 mg/dL;平均 LDH 峰值为 230 ± 55(mg/dl);纤维蛋白原平均峰值为 223 ± 40(mg/dl)。
在我们的经验中,Eurosets A.L.ONE ECMO 成人聚甲基戊烯纤维氧合器的性能在长期治疗中证明了在摄取氧和去除二氧化碳、血液动力学、代谢补偿和热量交换方面的效率。该设备在接受 VA ECMO 的患者中使用 14 天内以及在所有接受持续抗凝治疗的 VV ECMO 的患者中均安全,无医源性问题。